# Scott Williams
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/scott-williams/
## Facts
| Field | Value |
| --- | --- |
| Citations | 17,366 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 56 |
| i10-index | 134 |
| OpenAlex ID | https://openalex.org/A5082622296 |
| ORCID iD | https://orcid.org/0000-0002-1357-0884 |
| Works | 271 |
## Researcher papers
- [Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study](https://scholariq.org/papers/prostate-specific-membrane-antigen-pet-ct-in-patients-with-high-risk-prostate/)
- [Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer](https://scholariq.org/papers/enzalutamide-with-standard-first-line-therapy-in-metastatic-prostate-cancer/)
- [\[177Lu\]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study](https://scholariq.org/papers/177lu-psma-617-radionuclide-treatment-in-patients-with-metastatic-castration/)
- [\[177Lu\]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial](https://scholariq.org/papers/177lu-lu-psma-617-versus-cabazitaxel-in-patients-with-metastatic-castration/)
- [Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes](https://scholariq.org/papers/dosimetry-of-sup-177-sup-lu-psma-617-in-metastatic-castration-resistant-prostate/)
- [Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial](https://scholariq.org/papers/adjuvant-radiotherapy-versus-early-salvage-radiotherapy-following-radical/)
- [Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/long-term-follow-up-and-outcomes-of-retreatment-in-an-expanded-50-patient-single/)
- [PSMA and FDG-PET as predictive and prognostic biomarkers in patients given \[177Lu\]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial](https://scholariq.org/papers/psma-and-fdg-pet-as-predictive-and-prognostic-biomarkers-in-patients-given-177lu/)
- [Overall survival with \[177Lu\]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial](https://scholariq.org/papers/overall-survival-with-177lu-lu-psma-617-versus-cabazitaxel-in-metastatic/)
- [Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy](https://scholariq.org/papers/poor-outcomes-for-patients-with-metastatic-castration-resistant-prostate-cancer/)
## Researcher topics
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Advanced Radiotherapy Techniques](https://scholariq.org/topics/advanced-radiotherapy-techniques/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.